REACT is under clinical development by Prokidney and currently in Phase III for Type 2 Diabetes. According to GlobalData, Phase III drugs for Type 2 Diabetes have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how REACT’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
REACT is under development for the treatment of chronic kidney disease, congenital anomalies of the kidney and urinary tract (CAKUT), type I diabetes and type II diabetic patients. It is administered through intra-renal injection. The therapy is composed of autologous renal cells (neo-kidney augment) formulated in a gelatin-based hydrogel. The therapeutic candidate is developed based on organ regeneration technology.
Prokidney is a biotechnology company that develops cell therapy platform to treat multiple chronic kidney diseases. The company is headquartered in Winston-Salem, North Carolina, the US.
For a complete picture of REACT’s drug-specific PTSR and LoA scores, buy the report here.